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ABSTRACT 
In the present study an attempt has been made to formulate and evaluate a sustained release periodontal film of Sparfloxacin with 
biodegradable, cost effective polymer Chitosan. The objective of the study was to formulate intra-pocket periodontal films, which could be easily 
placed into the periodontal pocket, and thus be capable of delivering therapeutic concentrations of drug. Sparfloxacin is an antibiotic, showing 
wide spectrum antibacterial activity against a number of periodontal pathogens. Hence Sparfloxacin is selected as model for site specific 
delivery, i.e., into periodontal pocket for the treatment of periodontitis. In the present investigation Chitosan films containing Sparfloxacin were 
prepared by solution casting method using acetic acid. The copolymers HPMC K4M, Sodium CMC and Eudragit RL 100 in the concentrations of 
10%, 20% and 30% w/w of Chitosan were added into the polymeric solution. Propylene glycol was used as plasticizer. FT-IR and UV 
spectroscopic methods revealed no interaction between Sparfloxacin and polymers. The drug loaded films were evaluated for their thickness, 
weight variation, content uniformity, tensile strength, percent elongation, percentage moisture loss, surface pH, folding endurance, in- vitro drug 
release studies, in - vitro antibacterial activity and stability studies. Periodontal films showed initial burst release of drug on 1st day and then the 
release was sustained for a period of 8 days. In – vitro antibacterial activity was carried out on staphylococcus aureus and the antibacterial 
activity was retained for 96 hours. In - vitro release from periodontal films was fit to kinetic models to reveal drug release kinetics.  
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The term Periodontitis comes from two terms “peri’ = 
around, “odont” = tooth, “itis” = inflammation.1 Periodontal 
diseases are infections of the structures around the teeth, 
which include the gums, periodontal ligament and alveolar 
bone.2 Periodontal diseases include conditions such as 
chronic periodontitis, aggressive periodontitis, systemic 
diseases associated periodontitis and necrotizing 
periodontitis.3 This pocket provides an ideal environment for 
the growth and proliferation of anaerobic pathogenic 
bacteria.4 Clinically, as the disease progresses, the 
periodontal pocket, which is somewhat deeper than the 
sulcus of a healthy tooth, gets deeper with further 
destruction of the tooth’s supporting structures, often 
resulting in tooth loss.5 The microorganisms colonizing the 
subgingival area represent the principal etiological factor in 
the development of the inflammation and tissue 
destruction.4 
There are many antimicrobial agents used in the 
management of periodontal diseases. Tetracyclines and 
metronidazole are the agents most frequently used in the 
management of periodontal disease.6 The diagnosis of 
periodontal conditions is often made on clinical grounds, but 
microbial sampling of pocket flora is of value in determining 
the type of antimicrobial therapy. Although a number of 
bacterial species are thought to be associated with 
periodontitis, few attempts have been made to detect 
bacterial species comprehensively from periodontal sites. 
Two species (Mogibacterium timidum and Porphyromonas 
gingivalis) were detected significantly more frequently in 
subgingival plaque of periodontitis subjects than of healthy 
subjects, suggesting that these two species are closely 
related to periodontitis.7 Porphyromonas gingivalis is a Gram-
negative anaerobe that has been strongly implicated as an 
etiological agent in human periodontal diseases. It produces 
a wide range of proteolytic enzymes that might potentially 
act as virulence factors.8 
Naik et al                                                                                                                          Journal of Drug Delivery & Therapeutics. 2019; 9(1):38-45 
ISSN: 2250-1177                                                                                  [39]                                                                                 CODEN (USA): JDDTAO 
In present study Sparfloxacin was selected as the model 
antibacterial drug which is against gram-positive bacteria 
(especially Streptococus pneumonia, Staphylococcus, 
Enterococcus), Bacteroides fragilis, other anaerobes and 
mycobacteria.5  Periodontal film was formulated using 
Chitosan as Biodegradable Polymer along with in varying 
concentrations bio-adhesives polymers (HPMC K4M, Sodium 
CMC, Eudragit RL 100). Various pharmaceutical quality 
control tests were carried out to evaluate drug loaded 
periodontal films. Films were also tested for their suitability 
in periodontitis. 
MATERIALS AND METHODS 
Materials 
Sparfloxacin was received from Aristo Pharmaceuticals Pvt. 
Ltd, Mumbai as a free gift sample. Chitosan as Biodegradable 
Polymer was purchased from Loba Chemie Ltd, sodium 
carboxy methyl cellulose as mucoadheesive polymer and 
Dibutyl phthalate as Plasticizer were purchased from Sd- fine 
chem limited, Mumbai, HPMC K4M as a Mucoadhesive 
Polymer was received from Colorcon Asia Pvt. Ltd. Goa. 
Eudragit RL 100 was purchased from Ozone International, 
Mumbai. Propylene glycol as Plasticizer was purchased from 
Chemport (India) Private Limited, Mumbai. Acetic acid as a 
Solvent was purchased from Loba Chemie Ltd. Mueller 
Hinton Agar Medium, Soyabean Casein Digest Medium 
(Tryptone Soya Broth) were purchased from Himedia 
Laboratories Pvt. Ltd. 
Preformulation studies 
The sample of Sparfloxacin was subjected to UV Spectral 
analysis, λ max determination; IR Spectral analysis and 
Melting point determination for confirm identity and purity 
of drug sample. Drug-excipient compatibility study was 
carried out using FTIR spectroscopy. 
Calculation of Sparfloxacin dose to be incorporated in 
the Periodontal Films 9 
Sparfloxacin is available in the market as a tablet (200 mg). 
The dose recommended for the treatment of anaerobic 
infection is 0.5g to 1g i.v., followed by 1 g daily as a single or 
in two divided doses for 5 to 10 days. Thus oral therapy with 
200 mg every 12 hours is substituted as soon as possible. As 
the dose of sustained release film is reduced to 1/400 that of 
the tablet form therefore a dose of 0.5 mg per periodontal 
film was fixed.  
Internal diameter of petridish       =    8.8 cm 
Internal surface area of petridish =    πr 2 
                                               =           22 / 7 × (4.4)2 
                                               =           60.83 cm2 
                                                                =            6083 mm2 
Surface area of Periodontal film  =  0.6 × 0.2 cm2 
                                                  =         0.12 cm2 
                                                  =          12 mm2 
Therefore, 12 mm2 contains  0.5 mg of Sparfloxacin 
                     6083 mm2 contains  x mg of Sparfloxacin 
      x = 253.4 mg of Sparfloxacin 
Preparation of drug loaded Periodontal Films 
Periodontal Films were prepared by solvent casting 
technique; formulation of film is given in Table 1. An 
accurately weighed amount of Chitosan (2%w/v) was 
soaked in aqueous acetic acid (1%v/v) for 24 hours to get a 
clear solution, which was filtered through muslin cloth to 
remove undissolved polymer (chitin). Then, the accurately 
weighed amounts of copolymers (HPMC K4M, Sodium CMC, 
Eudragit RL 100) in varying concentrations (10%, 20%, 30% 
w/w) of Chitosan were added. Mixing was continued until a 
clear solution of polymers in solvent was obtained. After the 
complete dissolution of the polymer, plasticizer was added 
to the polymer solution (Propylene glycol). Accurately 
weighed amount of drug (Sparfloxacin) was homogenously 
dispersed in the above polymeric solution by constant 
stirring. After complete mixing, the beaker was kept aside for 
10 minutes to remove the entrapped air bubbles. This 
dispersion was then poured into aluminium lined clean glass 
petri-dishes placed on a level platform. The solvent was 
allowed to evaporate under controlled conditions by 
covering the petri-dishes with a glass funnel by placing a 
loose cotton plug into the stem of funnel at room 
temperature for 24 hours. After complete evaporation of 
solvent, cast films were obtained were then cut into pieces of 
6 × 2 mm2, wrapped into aluminium foil and stored in 
dessicator at room temperature till further evaluation 
studies.
 
Table 1: Formulation of Sparfloxacin Periodontal Films 
Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
Sparfloxacin (mg) 253 253 253 253 253 253 253 253 253 253 
Chitosan (mg) 200 200 200 200 200 200 200 200 200 200 
HPMC K4M 
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Propylene glycol (ml) 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 
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Evaluation of drug loaded Periodontal Films: 
1. Appearance 10 
The drug loaded periodontal films were observed for colour 
and physical form or appearance. 
2. Thickness uniformity of the films 11 
The thickness of each film was measured using screw guage 
(thickness tester) at different positions of the film and the 
average was calculated. 
3. Uniformity of weight of the films 11 
Drug loaded periodontal films (6×2mm2) were cut from 10 
different places of the same formulation and weighed on 
electronic balance and the average weight was calculated. 
4. Surface pH 12 
Drug loaded Periodontal films were left to swell for 1 hour 
on the surface of the agar plate, prepared by dissolving 2% 
w/v agar in warmed double distilled water with constant 
stirring and poured into the petridish to solidify at room 
temperature. The pH paper was placed on the surface of the 
swollen film and the pH was determined. The mean of three 
readings was recorded. 
5. Folding endurance 10,13 
The folding endurance is expressed as the number of folds 
(number of times the film is folded at the same place, either 
to break the strip/ film or to develop visible cracks). This test 
gives an indication of brittleness. The drug loaded 
periodontal films was folded in the centre, between the 
fingers and the thumb and then opened. This was termed as 
one folding. The process was repeated till the film showed 
rupture (d) or cracks in centre of film or folded up to 100 
times which is considered satisfactory to reveal good film 
properties. The total numbers of foldings were named as 
folding endurance value. This test was carried out on all the 
drug loaded films for three times and the mean of three 
readings was recorded. 
6. Tensile strength and Percent elongation14,15  
Simple type of apparatus for laboratory use has been 
designed for measuring tensile strength and percent 
elongation. 
 
Figure 1: Locally designed Tensile strength and Percent 
elongation tester 
It consists of Dynamometer with scale expressed in Newton 
and Gram. The end of the dynamometer consists of weighing 
pan attached to dynamometer by means of hook. A drug 
loaded periodontal film of size (approximately 3×1 cm2) was 
cut on a glass plate with a sharp blade, so that it had a 
smooth margin and its dimensions were determined. Both 
the ends of the film were fixed between adhesive tape one 
end being attached to dynamometer and the other end 
attached to weighing pan to give support to the film and to 
keep the film straight while stretching. To determine the 
percent elongation and tensile strength, weights were 
gradually added to the weighing pan to increase the pulling 
force till the film ruptured.  
Percent elongation was calculated by applying the following 
equation:  
                   
                  
               
       
Tensile strength was calculated after the film ruptured by 
observing the break force that is directly been noted from 
the tester. The force is given in Newton and the tensile 
strength is calculated by applying the following equation: 
                   
                  
                                             
 
7. Percentage moisture loss 11 
6 films of different concentrations of size (6×2 mm) were 
weighed accurately, and then, they were kept in desiccators 
for 3 consecutive days and then reweighed. The percentage 
moisture loss was calculated by the applying the following 
equation: 
                        
                             
             
      
8. Drug content uniformity 11 
The prepared film formulations were analyzed for drug 
content by taking film (size of 6×2 mm) from each batch and 
individually dissolved in 5 ml of pH 6.6 phosphate buffer in a 
beaker. The dispersion was kept overnight in dark place. The 
dispersion was filtered. Then 0.1 ml of the filtered solution 
was diluted to 10 ml with phosphate buffer of pH 6.6 in a 10 
ml volumetric flask. Drug concentrations were determined 
by taking three readings, using a UV visible 
spectrophotometer at 290 nm.  The polymeric solution 
without drug served as blank.  
9. Accelerated stability studies 16 
Stability of pharmaceutical preparation can be defined as the 
“capability of particular formulation in a specific system to 
remain within its physical, chemical, microbiological, 
therapeutic and toxicological specifications throughout its 
shelf life”. The purpose of stability testing is to provide 
evidence on how the quality of a substance or drug product 
varies with time under the influence of variety of 
environmental factors such as temperature, humidity, and 
light, enabling recommended storage conditions re-test 
periods and shelf-lives to be established.  
ICH guidelines: 
Long-term testing 25 ± 20C/60% ± 5% RH for 12 months. 
Accelerated testing 40 ± 20C/75% ± 5% RH for 6 months. 
Procedure: 
The drug loaded periodontal films were subjected to short 
term stability testing. The films of size 6×2mm2 were 
weighed and wrapped in aluminium foil, and placed in 
petriplates which were kept in a stability chamber 
maintained at 40 ± 20C and 75 ± 5% RH for 1 month. Changes 
in the appearance and drug content of the stored films were 
investigated during the period and after 3 months. 
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10. In-vitro drug release study 11 
The pH of gingival fluid lies between 6.5-6.8, thus phosphate 
buffer pH 6.8 was used as simulated gingival fluid. A static 
dissolution model was adopted for the dissolution studies as 
the film should be immobile in the periodontal pocket. Films 
of known weight and dimension (6×2mm2) were placed 
separately in small vials sealed with rubber closures 
containing  .  ml of phosphate buffer  p   .   and  ept at 
    C for 8 days. In interval of 1 day, the buffer was drained 
off and replaced with fresh phosphate buffer of pH 6.6. The 
drained buffer solution was suitably diluted to 10 ml with 
phosphate buffer pH 6.6 and the concentration of the drug in 
the buffer was determined by UV Spectrophotometry at 290 
nm. The procedure was continued for 8 days and the 
cumulative percentage of drug release was calculated and 
plotted against time. 
11. In-vitro antibacterial activity 17  
Formulation: Periodontal Films of 25 mm2 containing 0.89 
mg of drug (Sparfloxacin) 
Disc Diffusion Procedure 
Media Used: Mueller Hinton Agar Medium and Soyabean 
Casein Digest Medium.                           
Temperature: Agar plates are brought to room temperature 
before use. 
Procedure: 
a. Using a loop or swab, the colonies of Staphylococcus 
aureus (aerobic gram positive organism i.e. commonly 
found in Periodontitis) were transferred to the tube 
with Soyabean casein digest medium. 
b. The tube was then rotated in between the palms and 
then was allowed to incubate for  2 hrs. at   ˚C. 
c. Uninnoculated sterile Mueller Hinton Agar Medium was 
poured into sterile petriplates (approx. 10 ml) and was 
allowed to solidify for 15 mins. 
d. Innoculated sterile Soyabean Casein Digest Medium was 
then overlayered on top of the previously solidified agar 
plate. 
e. After 5 mins the drug loaded Periodontal films (5×5 
mm2) were placed on the semi dried inoculated plates 
using sterile forcep and press slightly in the centre of 
the film using the forcep so that strip gets adhered to 
the media which is important to show the activity of the 
Periodontal film. 
f. Plates were then incubated at 37ºC in incubator for 48 
hrs. 
g. After 48 hrs. of incubation the periodontal films were 
transferred to freshly seeded agar plates and incubated 
for an additional 48 hrs. 
h. The diameter of inhibition zone was measured to 
nearest whole millimetre by holding the measuring 
device. 
12. In- vitro Drug Release kinetics 12,18 
To analyse the mechanism for the drug release and release 
rate kinetics of the dosage form, the data obtained from in-
vitro drug release studies was fitted into four models of data 
treatment as follows: 
Zero order (cumulative percentage of drug released v/s 
time) 
First order (log cumulative percentage of drug remaining v/s 
time) 
Higuchi model (cumulative percentage of drug release v/s 
square root of time) 
Korsmeyer – Peppas model (log cumulative percentage drug 
release v/s log time). 
RESULTS AND DISCUSSION 
Periodontal films of Sparfloxacin were developed using 
different natural and synthetic polymers and characterized 
for various pharmaceutical parameters. The details of result 
and discussion are given in the following section.  
1. Identification of drug 
The received sample of Sparfloxacin was subjected to UV 
Spectral analysis and λ max determination, IR Spectral 
analysis and Melting point determination. The result thus 
obtained confirms the purity of drug sample. Excipients were 
investigated for their compatibility with Sparfloxacin using 
FTIR as non-thermal method of compatibility analysis. Based 
on the results of FTIR analysis the excipients were found to 
be compatible with Sparfloxacin. 
2. Appearance 
All the polymer combinations used for fabrication of 
periodontal films showed good film properties and 
reproducibility. The fabricated films were thin, flexible, 
elastic and smooth. 
3. Thickness uniformity of the films  
Thickness of each film was measured at six different points 
and average thickness with standard deviation was 
calculated. The thicknesses of various films are given in the 
Table 2. The data of film thickness indicates that there was 
no much difference in thickness within the formulations. 
4. Uniformity of weight of the films 
Drug loaded periodontal films (0.14cm2) were tested for 
uniformity of weight and the results of weight uniformity are 
given in the Table 2. The data of weight variation of films 
indicates that there was no much difference in weight 
variation within the formulations. 
5. Surface pH 
Surface pH of all the formulations were found to have pH 
between 6-7.This reveals that prepared films would not alter 
the pH of the gingival fluid in the periodontal pocket. Hence 
the chances of irritation are very less. 
6. Folding endurance of films 
Folding endurance value for the entire drug loaded 
periodontal films were found to be more than 50 folds. It 
indicates that all formulations had satisfactory film 
flexibility. 
7. Tensile strength and Percent elongation 
The tensile strength of all the drug-loaded periodontal films 
was studied and given in Table 3. The effective cross linking 
was observed on addition of Eudragit RL 100 as a copolymer, 
which also shows higher tensile strength when compared to 
other formulations. The tensile strength of the films were in 
the order of F10 > F9 > F8 > F7 > F6 > F5 > F4 >F3 > F2 > F1. 
The tensile strength was less for the F1 formulation 
(formulation without copolymer) and was higher for the 
films containing copolymer (30% w/w of Chitosan). As the 
concentration of copolymer increased tensile strength of the 
film also increased, this may be due to the increased 
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toughness and rigidity of the polymeric film. Percent 
elongation of all the drug loaded periodontal films was 
studied and given in Table 3. The order of percent elongation 
of the film is in the order of F9 > F10 > F8 > F7 > F6 > F5 > F3 
> F4 > F2 > F1. 
8. Percentage moisture loss 
Percentage moisture loss of all the drug loaded periodontal 
films was studied and given in Table 3. Low moisture loss 
helps the formulation to remain stable and prevent from 
being completely dried and brittle. The order of percentage 
moisture loss of the films is in the order of F6 > F1 > F5 > F3 
> F7 > F4 > F2 > F9 > F8 > F10. 
9. Drug content uniformity 
Percentage drug content of prepared formulations is given in 
Table 3. It was observed from the result that there was the 
uniformity in drug content and it was within pharmacopoeial 
limits. 
  














F1 0.334±0.00450 3.028±0.07527 6 78 
F2 0.334±0.00626 4.037±0.27868 6 86 
F3 0.339±0.00400 4.261±0.12247 7 80 
F4 0.362±0.01265 4.844±0.25033 6 94 
F5 0.333±0.00825 3.600±0.29097 7 92 
F6 0.336±0.00600 2.750±0.34496 6 88 
F7 0.363±0.01386 3.966±0.33262 7 95 
F8 0.354±0.00510 4.233±0.32659 6 94 
F9 0.339±0.00268 5.133±0.16329 7 78 
F10 0.349±0.00632 4.986±0.16329 7 90 
 
Table 3: Data of Tensile strength, per cent elongation, percentage moisture loss and drug content of drug loaded 














F1 0.543±0.057 10 7.75±3.560 93.73±1.769 
F2 0.643±0.045 11 5.97±2.635 95.97±0.711 
F3 0.734±0.097 14 7.29±1.351 93.94±1.658 
F4 0.831±0.089 13 6.28±1.584 95.30±1.424 
F5 0.982±0.056 16 7.59±1.761 94.83±1.086 
F6 1.360±0.057 17 9.48±6.805 92.70±3.141 
F7 1.376±0.049 19 6.47±2.592 96.62±1.488 
F8 1.500±0.063 20 5.79±0.463 86.90±2.034 
F9 1.576±0.084 25 5.93±2.698 89.10±0.636 
F10 1.586±0.011 23 5.03±0.666 88.70±0.699 
 
In-vitro drug release  
The data of percentage drug release from in-vitro studies of all formulations are shown in Tables 4 and Graph 1 and 2.   
Table 4: In-vitro Dissolution study data (Cumulative % drug release v/s time of F1 to F10) 
Time 
(days) 
Cumulative % drug released (n = 3) 
F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 
0 0±0.000 0±0.000 0±0.000 0±0.000 0±0.000 0±0.000 0±0.000 0±0.000 0±0.000 0±0.000 
1 57.0±1.210 71.0±0.231 65.0±0.347 73.0±0.225 25.0±0.245 66.0±0.129 64.0±0.369 74.0±0.268 18.0±3.247 14±0.112 
2 62.0±1.053 81.4±0.111 71.6±0.554 82.8±0.639 29.2±0.325 69.8±0.668 69.6±1.240 86.0±0.328 20.6±6.587 21.4±0.367 
3 63.2±0.285 83.4±0.365 76.8±0.147 85.8±0.489 30.2±0.887 72.2±0.850 73.0±3.221 89.2±1.287 24.6±0.257 26.4±0.945 
4 64.2±0.741 84.4±0.224 82.2±0.665 88.4±0.654 35.4±0.654 74.0±0.687 78.8±0.687 91.4±4.221 28.2±0.963 33.8±0.357 
5 68.8±0.358 85.2±0.335 84.2±0.331 89.4±0.664 39.2±0.025 76.8±0.544 83.0±1.325 97.8±3.224 33.8±0.374 44.2±0.331 
6 69.8±0.552 85.6±0.479 85.4±0.987 91.0±6.321 42.2±0.658 77.6±0.224 84.6±0.224 98.8±0.687 34.2±0.887 46.6±0.023 
7 720±0.321 86.4±0.894 86.0±0.259 91.4±0.367 46.8±0.369 78.6±0.360 85.6±0.398 99.2±0.369 40.2±0.950 53.6±0.874 
8 73.0±0.411 86.8±0.547 86.2±0.647 91.6±0.114 51.8±0.036 79.2±0.298 87.0±4.221 99.4±3.240 42.4±0.987 56.2±0.698 
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Graph 1: Comparative in-vitro drug release profile of 
Sparfloxacin loaded Periodontal films (F1 to F5) 
 
 
Graph 2: Comparative in-vitro drug release profile of 
Sparfloxacin loaded Periodontal films (F6 to F10) 
 
Stability studies: 
The formulations were subjected to stability studies at 40 ± 2 
0C and 75 ± 5% RH for 3 month as per ICH guidelines. Films 
were investigated for the appearance, surface pH, folding 
endurance and drug content during the period of stability 
study. The result thus obtained proves the stability of 
developed peridontal film. 
In–vitro antibacterial activity 
In-vitro antibacterial activity was performed using microbial 
strains of Staphylococcus aureus. The zones of inhibition 
formed due to Sparfloxacin loaded periodontal film 
formulations were observed after 48hrs and 96hrs of 
incubation. The results of antibacterial activity are shown in 
Table 5. The result of study showed that the antibacterial 




Figure 2: Zone of inhibition after 48 hrs of incubation of Sparfloxacin loaded periodontal films 
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Table 5:  In-vitro antibacterial activity of Sparfloxacin Periodontal films 
Formulations Zone of inhibition after 48 hrs of 
incubation (mm) 
Zone of inhibition after 96 hrs of 
incubation (mm) 
Total zone of inhibition 
(mm) 
F1 12 26 38 
F2 36 27 63 
F3 40 24 64 
F4 37 26 63 
F5 35 26 61 
F6 36 27 63 
F7 37 27 64 
F8 40 25 65 
F9 35 26 61 
F10 34 25 59 
 
Release Kinetics of formulations 
The in-vitro drug release data of prepared the Sparfloxacin 
loaded periodontal films were subjected to statistical 
analysis using linear regression analysis to ascertain the 
mechanism of drug release. The results of linear regression 
analysis including regression coefficient are presented in 
Table 6. The result obtained showed that the prepared film 
follows first order drug release kinetic and drug was 
released by diffusion mechanism. 
 
Table 6: Release Kinetics Profile of F1 – F10 formulations 
 
CONCLUSIONS 
Periodontal films of Sparfloxacin were designed using 
Chitosan, HPMC K4M, Na CMC and Eudragit RL 100 and 
evaluated for the physiochemical characteristics including 
in-vitro drug release. In vitro drug release studies were 
carried out by static dissolution method using pH 6.6 buffer 
solution for period of 8 days. All the films showed an initial 
burst release and then the release was controlled and 
extended for the period of study.  The study shows first 
order release of drug with diffusion mechanism. The 
prepared formulations were subjected for antimicrobial 
activity by using strains of staphylococcus aureus and the 
antimicrobial activity was retained for 96 hours. The 
formulations were subjected to stability studies, the results 
thus obtained showed no significant changes in the 
formulation.  
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